Data Insights

VAXINIA by Imugene for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

VAXINIA is under clinical development by Imugene and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Bile Duct Cancer (Cholangiocarcinoma)

Data Insights

VAXINIA by Imugene for Metastatic Melanoma: Likelihood of Approval

VAXINIA is under clinical development by Imugene and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Metastatic Melanoma

Data Insights

VAXINIA by Imugene for Pancreatic Cancer: Likelihood of Approval

VAXINIA is under clinical development by Imugene and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Pancreatic Cancer

Data Insights

VAXINIA by Imugene for Colorectal Cancer: Likelihood of Approval

VAXINIA is under clinical development by Imugene and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Colorectal Cancer

Data Insights

VAXINIA by Imugene for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

VAXINIA is under clinical development by Imugene and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Triple-Negative Breast Cancer (TNBC)

Data Insights

VAXINIA by Imugene for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval

VAXINIA is under clinical development by Imugene and currently in Phase I for Transitional Cell Cancer (Urothelial Cell Cancer). According...

Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Transitional Cell Cancer (Urothelial Cell Cancer)

Data Insights

VAXINIA by Imugene for Non-Small Cell Lung Cancer: Likelihood of Approval

VAXINIA is under clinical development by Imugene and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Non-Small Cell Lung Cancer

Data Insights

VAXINIA by Imugene for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval

VAXINIA is under clinical development by Imugene and currently in Phase I for Kidney Cancer (Renal Cell Cancer). According to...

Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Kidney Cancer (Renal Cell Cancer)

Data Insights

VAXINIA by Imugene for Solid Tumor: Likelihood of Approval

VAXINIA is under clinical development by Imugene and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Solid Tumor

Data Insights

VAXINIA by Imugene for Hepatocellular Carcinoma: Likelihood of Approval

VAXINIA is under clinical development by Imugene and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Hepatocellular Carcinoma

Data Insights

VAXINIA by Imugene for Bladder Cancer: Likelihood of Approval

VAXINIA is under clinical development by Imugene and currently in Phase I for Bladder Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Bladder Cancer

Data Insights

VAXINIA by Imugene for Gastric Cancer: Likelihood of Approval

VAXINIA is under clinical development by Imugene and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Gastric Cancer

Data Insights

VAXINIA by Imugene for Head And Neck Cancer: Likelihood of Approval

VAXINIA is under clinical development by Imugene and currently in Phase I for Head And Neck Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Head And Neck Cancer

Data Insights

VAXINIA by Imugene for Liver Cancer: Likelihood of Approval

VAXINIA is under clinical development by Imugene and currently in Phase I for Liver Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Liver Cancer